Supernus Pharmaceuticals (SUPN) Scheduled to Post Earnings on Monday

Supernus Pharmaceuticals (NASDAQ:SUPN) will issue its quarterly earnings data after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Supernus Pharmaceuticals has set its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The firm had revenue of $168.30 million during the quarter, compared to the consensus estimate of $148.83 million. During the same quarter last year, the business earned ($0.02) EPS. The business’s revenue was up 24.1% compared to the same quarter last year. On average, analysts expect Supernus Pharmaceuticals to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $33.93 on Monday. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -117.00 and a beta of 0.88. The company has a 50-day moving average of $33.05 and a two-hundred day moving average of $30.31. Supernus Pharmaceuticals has a 52-week low of $21.99 and a 52-week high of $35.44.

Analysts Set New Price Targets

SUPN has been the topic of a number of research analyst reports. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.